Purpose: The purpose of this study was to investigate the level of adherence to antipsychotic prescription medication in a well-defined homeless cohort over a 15-year period. We hypothesized that adherence would be well below the recommended threshold for clinical effectiveness (80 %), and that it would be strongly associated with modifiable risk factors in the social environment in which homeless people live.
Method: Linked baseline data (including comprehensive population-level administrative prescription records) were examined in a subpopulation of participants from two pragmatic-randomized trials that investigated Housing First for homeless and mentally ill adults. Adherence to antipsychotic medication was operationalized using the medication possession ratio. Multivariable logistic regression was used to estimate effect sizes between socio-demographic, homelessness-related and illness factors, and medication possession ratio.
Results: Among the 290 participants who met inclusion criteria for the current analysis, adherence to antipsychotic prescription was significantly associated with: history of psychiatric hospitalization; receipt of primary medical services; long-acting injectable antipsychotic formulations; and duration of homelessness. Mean medication possession ratio in the pre-randomization period was 0.41. Socio-demographic characteristics previously correlated with antipsychotic non-adherence were not significantly related to medication possession ratio.
Conclusions: This is the first study to quantify the very low level of adherence to antipsychotic medication among homeless people over an extended observation period of 15 years. Each of the four factors found to be significantly associated with adherence presents opportunities for intervention. Strategies to end homelessness for this population may represent the greatest opportunity to improve adherence to antipsychotic medication.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5091737 | PMC |
| http://dx.doi.org/10.1007/s00127-016-1259-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Differentiating aspects of oral and long-acting injectable antipsychotic drugs for tailoring the therapy of schizophrenia in clinical practice: a narrative review.
Int Clin Psychopharmacol
January 2025
Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), Section of Psychiatry, University of Genoa.
Schizophrenia is a serious psychiatric condition requiring continuous treatment with antipsychotic medications available in different formulations, including oral antipsychotics (OAPs) and long-acting injectables (LAIs). This narrative review aims to comprehensively outline the advantages and disadvantages of OAPs and LAIs to support clinicians in choosing different formulations based on the presentation of clinical symptoms. An electronic search of the PubMed database was performed in June 2024, and additional articles were retrieved from the references or personal knowledge of the authors.
View Article and Find Full Text PDFEvaluation of the impact of refined nursing care on schizophrenia patients.
Medicine (Baltimore)
January 2025
Department of PICU2, Wudong Hospital of Wuhan, Wuhan, Hubei, China.
This study evaluates the impact of refined nursing interventions on patients with schizophrenia, focusing on disease severity, cognitive function, medication adherence, quality of life, and medication-related complications. The aim is to provide evidence for enhancing future clinical treatments. From January 2022 to January 2024, 201 schizophrenia patients were enrolled based on specific inclusion and exclusion criteria.
View Article and Find Full Text PDFPsychopathology trajectories and relapse in first episode schizophrenia with assured long-acting injectable adherence over 24 months.
Schizophr Res
January 2025
Faculty of Medicine and Health Sciences, Department of Psychiatry, Stellenbosch University, Tygerberg, 7500 Cape Town, South Africa.
Background: Relapse following a first episode of schizophrenia (FES) is common and often results in serious adverse psychosocial consequences. Treatment non-adherence is a key risk factor for relapse, but why relapse occurs despite antipsychotic treatment adherence remains unclear. This study examined the differences in FES psychopathology trajectories over 24-months with assured long-acting injectable antipsychotic (LAIA) treatment, to control for treatment adherence between those who relapsed and those who did not and what moderates these group differences.
View Article and Find Full Text PDFReal-World Effectiveness of Long-Acting Injectable and Oral Antipsychotic Agents in US Medicare Patients with Schizophrenia.
Adv Ther
January 2025
Division of General Internal Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Introduction: Daily oral antipsychotics (OAPs) are the mainstay of schizophrenia treatment; however, long-acting injectable antipsychotics (LAIs) are associated with better treatment adherence and improved outcomes.
Methods: This study assessed the real-world comparative effectiveness of LAIs and daily OAPs using claims data from a nationally representative sample of fee-for-service Medicare beneficiaries with schizophrenia. Antipsychotic discontinuation, psychiatric hospitalization, and treatment failure were compared relative to different reference groups using within-individual Cox regression models.
Physicians' and patients' perceived risks of chronic pain medication and co-medications in Quebec, Canada: a cross-sectional study.
BMC Prim Care
January 2025
Département des sciences de la santé, Université du Québec en Abitibi-Témiscamingue (UQAT), Rouyn-Noranda, Québec, Canada.
Background: The risks associated with medications and co-medications for chronic pain (CP) can influence a physician's choice of drugs and dosages, as well as a patient's adherence to the medication. High-quality care requires patients to participate in medication decisions. This study aimed to compare perceived risks of medications and co-medications between physicians and persons living with CP.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!